CKD-843
CKD-843 is in Phase 3 for androgenetic alopecia, developed by Chong Kun Dang Pharmaceutical.
A long-acting dutasteride injection intended to replace the daily capsule with a quarterly dose.
- Developed by
- Chong Kun Dang Pharmaceutical
- Current phase
- Phase 3
- Mechanism
- 5α-reductase inhibitor
- Indications
- Androgenetic alopecia
- Also known as
- CKD-843 A, CKD-843-R, CKD843
- Last public activity
- September 2026
- Copy last reviewed
- September 2026
- Record confidence
- Medium
Large confirmatory trials. The last step before filing.
Stops testosterone being converted into DHT, the hormone that drives pattern hair loss.
A research record, not medical advice: being listed here says nothing about whether a treatment works or whether it is right for you. Talk to a dermatologist about your own case.
How it is meant to work
Reported by the sponsor as a depot formulation of dutasteride, the same dual 5-alpha-reductase inhibition already approved orally for male pattern hair loss in South Korea and Japan. What is being tested is the delivery, not the mechanism.
Why it matters
Adherence is the quiet failure mode of a daily antiandrogen, and a quarterly injection addresses it directly. The Phase 3, recruiting since April 2025, plans to enrol 288 men and compares two dose levels against both placebo and oral dutasteride, which is the right comparator and a more demanding one than placebo alone. Primary completion is estimated for September 2027.
Development history
- Phase 1Phase 3
First Phase 3 trial on record: NCT06916793 — A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia
ClinicalTrials.gov ↗ - Phase 1
First Phase 1 trial on record: NCT04805606 — A Clinical Traial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of CKD-843
ClinicalTrials.gov ↗
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia
Chong Kun Dang Pharmaceutical · n=288 · April 2025
The Parallel Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of CKD-843 A
Chong Kun Dang Pharmaceutical · n=41 · November 2022
A Clinical Traial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of CKD-843
Chong Kun Dang Pharmaceutical · n=40 · April 2021
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia — ClinicalTrials.gov
- Chong Kun Dang accelerates developing new hair loss treatment 'CKD-843' — Press
- Report on the Deliberation Results, Zagallo Capsules (dutasteride), androgenetic alopecia in men; notes the South Korean approval — Regulator filing, September 2015
Related programmes
Other programmes in the register with the same mechanism: 5α-reductase inhibitor.
Cite this page
Hair Pipeline, "CKD-843 — development record", hairpipeline.com/pipeline/ckd-843